RxDoctor Payments Data

Jae Youn Lee, MD

Ophthalmology · Columbia, SCNPI 1881089571

Payments from drug & device makers

$1,746in general payments, 2019–2025

Across 63 payments — averaging $27.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$422
  • AbbVie$378
  • Sun Pharmaceutical Industries Inc.$179
  • Kala Pharmaceuticals, Inc.$99
  • Johnson & Johnson Surgical Vision, Inc.$97
  • Glaukos Corporation$86
  • plus $485 from 11 others

What the payments were for

  • Food & beverage$1,746100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,746 in reported general payments places this provider in the 45th percentile of 293 ophthalmology providers in South Carolina.

See all ophthalmology providers in South Carolina

Medicare billing

Part B allowed, 2024
$348,148
Medicare patients
1,169
Services billed
3,262

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost227$116,464
RestasisCyclosporine65$74,000
Cyclosporine43$23,773
XiidraLifitegrast21$16,474
RhopressaNetarsudil Mesylate22$14,006
RocklatanNetarsudil Mesylat/Latanoprost29$13,272
SimbrinzaBrinzolamide/Brimonidine Tart38$12,766
Prednisolone Acetate208$12,085
CombiganBrimonidine Tartrate/Timolol23$10,267
Brimonidine Tartrate387$9,240
Latanoprost593$8,939
Bromfenac Sodium51$8,165
Timolol Maleate247$7,709
ProlensaBromfenac Sodium21$7,447
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol23$6,947

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan$378$200,732315 claims
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$35$27,27851 claims
Bausch & Lomb Americas Inc.Xiidra$77$16,47421 claims
AlconSimbrinza$75$12,76638 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa$18$7,44721 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 293 ophthalmology providers in South Carolina.

Other ophthalmology in Columbia

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →